CYBB antibodies are immunoglobulin reagents designed to detect and quantify the CYBB protein, encoded by the CYBB gene. CYBB is essential for the NADPH oxidase complex, which generates reactive oxygen species (ROS) critical for microbial killing in phagocytes . Dysregulation of CYBB is linked to chronic granulomatous disease (CGD), autoimmune disorders, and vascular pathologies .
CYBB antibodies are typically raised against synthetic peptides or recombinant protein fragments. For example:
ABIN750688: Targets residues 501–570 of human CYBB, with cross-reactivity in humans, mice, rats, rabbits, and chickens .
NBP2-41291: Validated for Western blot (1–2 µg/mL), immunohistochemistry (2 µg/mL), and immunocytochemistry (20 µg/mL) in rodent and human tissues .
CYBB antibodies are pivotal in studying:
Immune Dysregulation: CYBB in dendritic cells (cDCs) facilitates LC3-associated phagocytosis (LAP), enabling myelin antigen presentation to encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE) .
Infection Models: Macrophage-specific CYBB mutations impair ROS production, increasing susceptibility to mycobacterial infections (e.g., X-linked Mendelian susceptibility to mycobacterial disease) .
Vascular Pathology: CYBB-generated ROS exacerbate diabetic retinopathy and peripheral artery disease, making it a therapeutic target .
Chronic Granulomatous Disease: Over 34 CYBB mutations disrupt NADPH oxidase activity, causing recurrent infections .
Autoimmunity: CYBB in cDCs licenses CD4+ T cells to invade the CNS in EAE, highlighting its role in neuroinflammation .
Therapeutic Targeting: Antioxidants or CYBB inhibitors improve arterial dilation in peripheral artery disease and reduce vascular injury in diabetic retinopathy .
Emerging studies emphasize CYBB’s role beyond innate immunity: